年龄、衰弱与多病共存对ICU干预效果的影响:随机对照试验的系统评价
该系统评价检索2011年1月1日至2021年12月31日发表于顶级综合医学与重症医学期刊的ICU干预RCT,纳入报告年龄、衰弱或多病共存任一亚组的试验,排除整群RCT、未报告ICU干预及未报告相关亚组数据的研究,共纳入48项RCT、50779例受试者。结果7项(14.6%)RCT发现年龄存在统计学显著的效应修饰,而衰弱与多病共存亚组均未发现统计学显著的亚组效应;亚组可信度从极低到中等。作者认为多数ICU RCT未评估衰弱或多病共存亚组效应,年龄虽较常被考虑但切点不一且相对效应修饰罕见,尽管干预效果可能在不同年龄组间相似,基于患者个体偏好的共享决策仍须优先,并呼吁专门针对重症老年及衰弱/多病共存患者开展RCT。
要点
- 48项ICU干预RCT(50779例)中仅7项(14.6%)发现年龄存在统计学显著的效应修饰。
- 衰弱与多病共存亚组均未发现统计学显著的亚组效应。
- 亚组发现的可信度从极低到中等。
- 作者认为干预效果可能在不同年龄组间相似,但基于患者个体偏好的共享决策仍须优先。
- 作者认为专门针对重症老年或衰弱/多病共存患者开展RCT至关重要。
适用人群与场景
- 2011年1月1日至2021年12月31日发表的ICU干预RCT,共48项、50779例受试者,报告年龄、衰弱或多病共存任一亚组。
- 排除整群RCT、未报告ICU干预的研究、未报告年龄/衰弱/多病共存亚组数据的研究。
研究设计与关键结果
- 研究类型:系统评价,检索顶级综合医学与重症医学期刊,纳入48项RCT、共50779例受试者。
- 7项(14.6%)RCT发现年龄存在统计学显著的效应修饰;衰弱与多病共存亚组均未发现统计学显著的亚组效应。
- 亚组可信度采用效应修饰分析可信度评估工具(Instrument for assessing the Credibility of Effect Modification Analyses)评价,范围为极低到中等。
- 年龄作为亚组的切点在不同研究中不一致。
证据类型、等级与局限
- 证据类型:系统评价(纳入随机对照试验)。
- 局限:多数ICU RCT未评估衰弱或多病共存亚组效应;年龄亚组切点不一;相对效应修饰罕见;亚组可信度从极低到中等。
对床旁实践的改变
- 作者认为,尽管干预效果可能在不同年龄组间相似,基于患者个体偏好的共享决策仍须优先。
- 作者认为,专门针对重症老年或衰弱/多病共存患者开展RCT对进一步回答该研究问题至关重要。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To date, age, frailty, and multimorbidity have been used primarily to inform prognosis in older adults. It remains uncertain, however, whether these patient factors may also predict response to critical care interventions or treatment outcomes.
DATA SOURCES: We conducted a systematic search of top general medicine and critical care journals for randomized controlled trials (RCTs) examining critical care interventions published between January 1, 2011, and December 31, 2021.
STUDY SELECTION: We included RCTs of critical care interventions that examined any one of three subgroups-age, frailty, or multimorbidity. We excluded cluster RCTs, studies that did not report interventions in an ICU, and studies that did not report data examining subgroups of age, frailty, or multimorbidity.
DATA EXTRACTION: We collected study characteristics (single vs. multicountry enrollment, single vs. multicenter enrollment, funding, sample size, intervention, comparator, primary outcome and secondary outcomes, length of follow-up), study population (inclusion and exclusion criteria, average age in intervention and comparator groups), and subgroup data. We used the Instrument for assessing the Credibility of Effect Modification Analyses instrument to evaluate the credibility of subgroup findings.
DATA SYNTHESIS: Of 2037 unique citations, we included 48 RCTs comprising 50,779 total participants. Seven (14.6%) RCTs found evidence of statistically significant effect modification based on age, whereas none of the multimorbidity or frailty subgroups found evidence of statistically significant subgroup effect. Subgroup credibility ranged from very low to moderate.
CONCLUSIONS: Most critical care RCTs do not examine for subgroup effects by frailty or multimorbidity. Although age is more commonly considered, the cut-point is variable, and relative effect modification is rare. Although interventional effects are likely similar across age groups, shared decision-making based on individual patient preferences must remain a priority. RCTs focused specifically on critically ill older adults or those living with frailty and/or multimorbidity are crucial to further address this research question.
参考来源
- Perrella A, Geen O, Ahuja M, et al. Exploring the Impact of Age, Frailty, and Multimorbidity on the Effect of ICU Interventions: A Systematic Review of Randomized Controlled Trials. Crit Care Med. 2024. PMID: 38661459. doi:10.1097/CCM.0000000000006315
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。